Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment

Ca-A Cancer Journal for Clinicians

Volumn 51, Issue 5, 2001, Pages 290-315

  Köstler, Wolfgang J ^a   Hejna, Michael ^a   Wenzel, Catharina ^a   Zielinski, Christoph C ^b,c,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Int Medicine and Medical Experimental Oncology ^*

^c UNIVERSITY OF VIENNA   (Austria)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CHLORHEXIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; HYDROGEN PEROXIDE; HYDROXYUREA; IRINOTECAN; KAOLIN PECTIN; MELPHALAN; METHOTREXATE; MITHRAMYCIN; MITOTANE; NAVELBINE; POVIDONE IODINE; SUCRALFATE; TIOGUANINE; UNINDEXED DRUG; VINBLASTINE;

ARTICLE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; CRYOTHERAPY; DISEASE EXACERBATION; HEALTH CARE COST; HUMAN; IONIZING RADIATION; MORBIDITY; MOUTH HYGIENE; MOUTH MUCOSA; MUCOSA INFLAMMATION; MYCOSIS; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; RADIATION SHIELD; TREATMENT PLANNING; VIRUS INFECTION;

EID: 0035570382     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.51.5.290     Document Type: Article

References (233)

1. Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors
2. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer
3. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer
4. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial
5. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts
6. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
7. Research advances in oral mucositis
8. Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy
9. Oral complications in patients receiving treatment for malignancies other than of the head and neck
10. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients
11. Proliferation and differentiation of gastrointestinal cells in relation to therapy
12. Chlorhexidine prophylaxis for chemotherapy-and radiotherapy-induced stomatitis: A randomized double-blind trial
13. Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy
14. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia
15. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation
16. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy
17. Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients
18. Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity
19. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3
20. Clinicopathologic effects of cancer chemotherapeutic agents on human buccal mucosa
21. Oral complications of cancer chemotherapy in pediatric patients
22. Epidermal growth factor and related molecules
23. Prevention and management of oral mucositis induced by antineoplastic therapy
24. Re: Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity
25. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
26. Effect of two oral care protocols on the incidence of stomatitis in hematology patients
27. The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma
28. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
29. Cancer chronotherapy
30. Parotid gland function during and following radiotherapy of malignancies in the head and neck. A consecutive study of salivary flow and patient discomfort
31. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis
32. Smoking and mucosal reactions to radiotherapy
33. The radiobiological basis for tissue reactions in the oral cavity following therapeutic x-irradiation. A review
34. Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: Potential for improved therapeutic efficacy
35. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: A randomised controlled trial comparing two protocols of dental care
36. Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies
37. Oral complications of cancer therapies. Management of salivary dysfunction
38. The effect of radiation-induced xerostomia on saliva and serum lysozyme and immunoglobulin levels
39. Effect of radiation-induced xerostomia on human oral microflora
40. Diagnosis and management of acute and chronic oral complications of nonsurgical cancer therapies
41. Scoring oral mucositis
42. Oral toxicity of chemotherapeutic agents
43. Pretreatment oral assessment
44. The oral flor as a source of septicemia in patients with acute leukemia
45. Pretherapy dental status of patients with malignant conditions of the head and neck
46. Oral complications of cancer chemotherapy: Present status and future studies
47. Effect of oral hygiene on stomatitis in patients receiving cancer chemotherapy
48. Dental care for patients receiving chemotherapy
49. Oral care for the cancer patient
50. Oral infections and septicemia in immunocompromised patients with hematologic malignancies
51. The incidence of oral herpes simplex virus infection in patients undergoing cancer chemotherapy
52. Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients
53. Oral complications of cancer therapies. Essential aspects of a pretreatment oral examination
54. Pretreatment strategies for infection prevention in chemotherapy patients
55. Mouth care for nasopharyngeal cancer patients undergoing radiotherapy
56. Nursing management of acute oral complications of cancer
57. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer
58. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients
59. Artificial salivas: Present and future
60. Effectiveness of pilocarpine in postradiation xerostomia
61. National Institutes of Health consensus development conference statement: Oral complications of cancer therapies: Diagnosis, prevention, and treatment
62. Enhancing the effect of oral hygiene with the use of a foam brush with chlorhexidine
63. Dental extractions in patients with acute nonlymphocytic leukemia
64. The safety of dental extractions in patients with hematologic malignancies
65. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis
66. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis
67. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy
68. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: Amelioration of dose-limiting mucositis by ice chip cryotherapy
69. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: A Southwest Oncology Group study
70. Prevention of high dose L-PAM-induced mucositis by cryotherapy
71. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients
72. [Prevention of oral mucositis in head and neck irradiation]
73. The role of oral microorganisms in cancer therapy
74. An animal model for mucositis induced by cancer chemotherapy
75. E. Oropharyngeal colonisation with fungi and gram-negative rods in patients treated with radiotherapy of the head and neck
76. Yeast flora of the mouth and skin during and after irradiation for oral and laryngeal cancer
77. [Yeast fungus flora in tumor irradiation of the upper aerodigestive tract]
78. Control of oral mucositis and candidiasis in marrow transplantation: A prospective, double-blind trial of chlorhexidine digluconate oral rinse
79. Infectious complications in the child with cancer. II. Management of specific infectious organisms
80. Clinical experience in prevention of candidiasis by nystatin in children with acute lymphocytic leukemia
81. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation
82. Evaluation of nystatin in prevention and elimination of oropharyngeal Candida in immunosuppressed patients
83. Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia
84. Prophylaxis of oropharyngeal candidiasis with clotrimazole
85. Oropharyngeal candidiasis treated with a troche form of clotrimazole
86. Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy
87. Prophylaxis of oropharyngeal candidiasis with fluconazole
88. Local antimicrobial therapy of oral mucositis in paediatric patients undergoing bone marrow transplantation
89. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis
90. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: A placebo-controlled double-blind trial
91. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group
92. Herpes virus infections: Clinical manifestations and therapeutic strategies in immunocompromised patients
93. Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation
94. The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients
95. E. Effect of acyclovir on radiation-and chemotherapy-induced mouth lesions
96. Periodontal infection in patients with acute nonlymphocyte leukemia. Prevalence of acute exacerbations
97. Oral gram-negative bacilli in bone marrow transplant patients given chlorhexidine rinses
98. Prevention of mucositis in irradiated head and neck cancer patients
99. Treatment of radiation-and chemotherapy-induced stomatitis
100. Clinical evaluation of MGI 209, an anesthetic, film-forming agent for relief from painful oral ulcers associated with chemotherapy
101. The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis
102. Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis
103. Patient-controlled versus staff-controlled analgesia with pethidine after allogeneic bone marrow transplantation
104. The effect of customized beam shaping on normal tissue complications in radiation therapy of parotid gland tumors
105. Devices valuable in head and neck radiotherapy
106. Decreased acute toxicity by using midline mucosa-sparing blocks during radiation therapy for carcinoma of the oral cavity, oropharynx, and nasopharynx
107. [Laser therapy in the prevention and treatment of mucositis caused by anticancer chemotherapy]
108. Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: A preliminary report
109. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients
110. Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double-blind randomized trial
111. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer
112. [Biochemical studies on camomile components/III. In vitro studies about the antipeptic activity of (-)-alpha-bisabolol (author's transl)]
113. Management of oral mucositis during local radiation and systemic chemotherapy: A study of 98 patients
114. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis
115. Prevention of oral mucositis in radiation therapy: A controlled study with benzydamine hydrochloride rinse
116. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy
117. Benzydamine HC1, a new agent for the treatment of radiation mucositis of the oropharynx
118. The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation
119. Comparative evaluation of benzydamine oral rinse in children with antineoplastic-induced stomatitis
120. [Radiotherapy of head-neck neoplasms: Prevention of inflammation of the mucosa by sucralfate treatment]
121. Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole
122. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. A double-blind placebo-controlled study
123. Sucralfate mouth washing in the prevention of radiation-induced mucositis: A placebo-controlled double-blind randomized study
124. Sucralfate for radiation mucositis: Results of a double-blind randomized trial
125. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy
126. Double-blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers
127. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis
128. Sucralfate in the treatment of chemotherapy-induced Stomatitis: A double-blind placebo-controlled pilot study
129. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study
130. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy
131. Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy
132. Topical PGE2 enhances healing of chemotherapy-associated mucosal lesions
133. Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis
134. Prostaglandin E2 for prophylaxis of oral mucositis following BMT
135. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers
136. The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: A preliminary study
137. Vitamin E in the treatment of chemotherapy-induced mucositis
138. Prophylactic glutamine protects the intestinal mucosa from radiation injury
139. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy
140. Oral glutamine to alleviate radiation-induced oral mucositis: A pilot randomized trial
141. 5-fluorouracil and folinic acid-induced mucositis: No effect of oral glutamine supplementation
142. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation
143. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity
144. Acute mucositis in the stimulated oral mucosa of patients during radiotherapy for head and neck cancer
145. Effects of stimulated repopulation on oral mucositis during conventional radiotherapy
146. [Clinical evaluation of sodium alginate on oral mucositis associated with radiotherapy]
147. Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis
148. Topical granulocyte-macrophage colony-stimulating factor in patients with cancer and impaired wound healing
149. Local use of GM-CSF for severe mucositis
150. Mucosal bioavailibility of GM-CSF given per os and by subcutaneous injection
151. GM-CSF mouthrinses in the treatment of severe oral mucositis: A pilot study
152. GM-CSF mouthwashes as treatment for mucositis in BMT patients
153. Effect of rh-granulocyte-macrophage colony-stimulating factor (GM-CSF) on oral mucositis
154. Local use of GM-CSF in the treatment of severe mucositis. A preliminary trial
155. Grade 3-4 stomatitis successfully treated with local GM-CSF (Leukomax)
156. Effect of granulocyte macrophage colony stimulating factor on chemotherapy induced oral mucositis in pediatric cancer patients
157. Effect of oral GM-CSF on intestinal permeability and systemic immune activation in chemotherapy-induced mucositis
158. A prospective randomized trial on the efficacy in GM-CSF mouthwashes for the treatment of chemotherapy-induced oral mucositis
159. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: A randomized, double-blind, dose-ranging study
160. Effect of topical oral G-CSF on oral mucositis: A randomised placebo-controlled trial
161. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy
162. [Use of standardized oral hygiene in the prevention and therapy of mucositis in patients treated with radiochemotherapy of head and neck neoplasms]
163. Treatment for irradiation-induced mucositis
164. Palliation of radiation-related mucositis
165. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy
166. Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis?
167. Oral capsaicin provides temporary relief for oral mucositis pain secondary to chemotherapy/radiation therapy
168. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma
169. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation
170. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation
171. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia
172. GM-CSF after allogeneic bone marrow transplantation: Accelerated recovery of neutrophils, monocytes and lymphocytes
173. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium
174. Effect of filgrastim (R-Methug-CSF) on oral mucositis in patients with small cell lung cancer receiving chemotherapy (Cyclophosphamide, Doxorubicin and Etoposide, CAE)
175. Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy
176. Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer
177. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study
178. Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: An interim look at a randomized, double-blind, placebo-controlled trial
179. The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy
180. Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study
181. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma
182. Amifostine-a radioprotector in locally advanced head and neck tumors
183. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
184. [Supportive use of amifostine in patients with head and neck tumors undergoing radiochemotherapy. Is it possible to limit the duration of the application of amifostine?]
185. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial]
186. Amifostine: A radioprotector in locally advanced head and neck tumors
187. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: A phase II study
188. Use of amifostine to reduce mucositis following total body irradiation (Tbi)-based autotransplants for lymphoma
189. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma
190. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis
191. T. Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azelastine) with other antioxidants
192. Propantheline prevention of mucositis from etoposide
193. Oral complications in bone marrow transplantation patients: Recent advances
194. Intravenous immunoglobulin as prophylaxis of chemotherapy-induced oral mucositis
195. Oral delivery of antibodies. Future pharmacokinetic trends
196. Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil
197. Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes
198. Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity
199. Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer
200. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis
201. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: A Southwest Oncology Group trial
202. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin
203. Oral complications of acute leukemia: Prophylactic impact of a chlorhexidine mouth rinse regimen
204. Effects of chlorhexidine during immunosuppressive chemotherapy. A preliminary report
205. Oropharyngeal mucositis complicating bone marrow transplantation: Prognostic factors and the effect of chlorhexidine mouth rinse
206. Effects of chlorhexidine mouthrinse on oral health in patients with acute leukemia
207. Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis
208. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis
209. Emergence of gram-negative bacilli in the mouths of bone marrow transplant recipients using chlorhexidine mouthrinse
210. Effect of nystatin and chlorhexidine digluconate on Candida albicans
211. Management of mucositis in oral irradiation
212. [The problem of radiogenic and chemotherapy-induced mucositis of the mouth and oropharynx exemplified by accelerated radiochemotherapy with carboplatin in patients with inoperable squamous epithelial carcinomas of Heidelberg experiences]
213. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation
214. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation
215. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients
216. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: A prospective, randomized trial
217. B. Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation
218. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications
219. A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis
220. [Pentoxifylline is not useful in the prevention of toxicity associated with bone marrow transplantation]
221. IL-11, a pleiotropic cytokine: Exciting new effects of IL-11 on gastrointestinal mucosal biology
222. Alteration in the frequency, severity and duration of chemotherapy- induced mucositis in hamsters by interleukin-11
223. Topical dehydroascorbic acid (DHA) reduced moderate to severe mucositis in the hamster acute irradiation model
224. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy
225. Keratinocyte growth factor (KGF) as a mucositis protectant: A randomized phase I trial
226. Improved pain management with daily nursing intervention during radiation therapy for head and neck carcinoma
227. WHO handbook for reporting the results of cancer treatment
228. Sucralfate in the prevention of radiation-induced oral mucositis
229. Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma
230. Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemoradiotherapy
231. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia
232. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia